Abstract:IMPORTANCE: Controversy exists around the American Joint Committee on Cancer (AJCC) TNM staging system for medullary thyroid cancer (MTC). Because of the rarity of the disease and limited available data, the staging system for MTC has been largely extrapolated from staging for differentiated thyroid cancer.OBJECTIVES: To evaluate how well the current (seventh and eighth editions) AJCC TNM staging system correlates with survival for patients with MTC and to suggest a possible revision.DESIGN, SETTING, AND PARTICIPANTS: This population-based retrospective cohort analysis used the National Cancer Database to select patients aged 18 years or older diagnosed with MTC in the United States between 1998 and 2012. Patient demographic and tumor characteristics were assessed, and pathologic tumor stages were provided as T, N, and M categories. Recursive partitioning with bootstrapping was used to divide patients by TNM stages into groups with similar survival. The newly identified groupings were validated in a Surveillance, Epidemiology, and End Results (SEER) cohort. Data analysis was conducted between July 17, 2016, and November 11, 2016.MAIN OUTCOMES AND MEASURES: Overall survival and disease-specific survival.RESULTS: Of the 3315 patients with MTC included in the analysis, 1941 (58.6%) were women. The median (interquartile range) age was 54 (42-65) years, and 2839 (85.6%) self-reported their race/ethnicity as white. The current AJCC TNM staging system classified 941 of these patients (28.4%) as stage I, 907 (27.4%) as stage II, 424 (12.9%) as stage III, and 1043 (31.5%) as stage IV. Recursive partitioning analysis yielded 4 TNM groups: stage I (T1N0-1aM0, T2N0M0), stage II (T1N1bM0, T2N1a-bM0, and T3N0M0), stage III (T3N1a-bM0, T4N0-1bM0), and stage IV (T1-4N0-1bM1). Based on these proposed TNM groupings, 1797 of the 3315 patients (54.2%) were classified as stage I, 684 (20.6%) as stage II, 669 (20.2%) as stage III, and 165 (5.0%) as stage IV. Under the proposed TNM groupings, survival differences across TNM groups were more distinct than under the current AJCC TNM staging system. With stage I as the reference, the hazard ratios of the proposed TNM groupings and the current AJCC TNM staging system were 2.19 (95% CI, 1.37-3.12) vs 1.45 (95% CI, 1.09-1.92) for stage II, 4.20 (95% CI, 2.75-5.75) vs 2.17 (95% CI, 1.59-2.89) for stage III, and 10.97 (95% CI, 5.52-18.57) vs 5.33 (95% CI, 4.13-6.86) for stage IV. In a SEER cohort, the proposed TNM groupings were better at discriminating survival than was the current AJCC TNM staging system.CONCLUSIONS AND RELEVANCE: The current AJCC TNM staging system for MTC appears to be less than optimal in distinguishing risk of mortality among stage groups, upstaging a significant number of patients to stage IV. The current AJCC TNM staging system could be improved with the new TNM groupings proposed here for more accurate risk stratification and potential treatment selection.

The Update of AJCC/TNM Staging System May Change the Post-Operative Assessment of Differentiated Thyroid Cancer

Patients Aged ≥55 Years with Stage T1-2N1M1 Differentiated Thyroid Cancer Should Be Downstaged in the Eighth Edition AJCC/TNM Cancer Staging System.

Assessment of the Prognostic Value and N1b Changes of the Eighth TNM/AJCC Staging System for Differentiated Thyroid Carcinoma

A Relook At The 8th Edition Of The Ajcc Tnm Staging System Of Anaplastic Thyroid Carcinoma: A Seer-Based Study

A Comparison of the Seventh and Eighth Editions of the AJCC Staging Systems to Predict Recurrence in Papillary Thyroid Microcarcinoma

Rethinking the 8th AJCC System: Is It Suitable for Patients Aged <55 Years With Stage T4N1M0 Follicular Variant of Papillary Thyroid Carcinoma to Be Placed in Stage I?

Rethinking the Current American Joint Committee on Cancer TNM Staging System for Medullary Thyroid Cancer

Is a Simplified TNM Staging System More Clinically Relevant Than the American Joint Committee on Cancer System for the Follicular Variant of Papillary Thyroid Cancer?

The evolution of the nasopharyngeal carcinoma staging system over a 10-year period: implications for future revisions

The prognostic value of lymph node metastasis and the eighth edition of AJCC for patients with anaplastic thyroid cancer

Survival in Papillary Thyroid Microcarcinoma: A Comparative Analysis Between the 7th and 8th Versions of the AJCC/UICC Staging System Based on the SEER Database

Clinical Validation of the Prognostic Stage Groups of the Eighth-Edition TNM Staging for Medullary Thyroid Carcinoma

Novel analysis of prognosis of young patients with stage II differentiated thyroid cancer based on AJCC 8.0 and 6.0 criteria to implement the staging system

New proposed tumor-node-metastasis staging system for medullary thyroid carcinoma based on the Surveillance, Epidemiology, and End Results database.

Evaluation of the Eighth Edition of the American Joint Committee on Cancer TNM Staging System for Gastric Cancer: an Analysis of 7371 Patients in the SEER Database

Evaluation of the 8th Edition of the American Joint Committee on Cancer's Pathological Staging System in Prognosis Assessment and Treatment Decision Making for Stage T1-2N1 Breast Cancer after Mastectomy.

Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma

Validation of the American Joint Commission on Cancer (8th Edition) Changes for Patients with Stage III Gastric Cancer: Survival Analysis of a Large Series from a Specialized Eastern Center.

Triple-negative breast cancer outcomes: Does AJCC 8th staging improve chemotherapy decision-making

Validation of the Eighth Edition of the TNM Staging System for Lung Cancer in 2043 Surgically Treated Patients With Non–small-cell Lung Cancer

Comparative Effectiveness of the Revised American Joint Committee on Cancer Staging System